Headquartered in Dublin, Ireland, ValitaCell provides analytical products and technologies for the biopharmaceutical industry intended to reduce new therapeutics' cost and time to market by empowering scientists with cell data and insights earlier in the drug discovery and development process.

"Together with Beckman Coulter Life Sciences, we will advance our shared ambition to accelerate and enable the sustainable manufacture of innovative biological medicines to bring them to market faster," said Dr. Jerry Clifford, co-founder and CEO of ValitaCell.

When it comes to immunoglobulin G quantification (IgG) assays, ValitaCell contends that its ValitaTiter product outperforms other techniques -- such as enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography (HPLC) -- in terms of speed and ease of use.

Jason Lanie, vice president of the biotechnology business unit at Beckman Coulter, noted that ValitaCell's "leading portfolio of products, including ValitaTiter, Quantum, CellAi, and ChemStress Clone Robustness complement Beckman Coulter's existing and future product portfolio and are designed with the same goal of providing faster cellular analysis while decreasing the risk of errors."

ValitaCell's Ireland locations, including Dublin and Galway, will remain operational and are anticipated to grow, the companies announced.